NRSN Live signals | Maximize Profits with Getagraph.com

SELL 104381 min ago

@ $1.320

Issued: 14 Feb 2024 @ 12:31

Return: -6.82%

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases...

Stats
Today's Volume	42 255.00
Average Volume	309 796
Market Cap	21.32M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $-0.190 ) 2024-05-25
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.480
ATR14	$0.0280 (2.28%)

Volume Correlation

Long: -0.14 (neutral)

Short: 0.07 (neutral)

Signal:(46.142) Neutral

NeuroSense Therapeutics Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NeuroSense Therapeutics Correlation - Currency/Commodity

0.46
( neutral )

0.40
( neutral )

0.00
( neutral )

0.51
( weak )

-0.43
( neutral )

0.17
( neutral )

NeuroSense Therapeutics Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-97 000.00 (0.00 %)
EPS:	$-0.830

FY	2023
Revenue:	$0
Gross Profit:	$-97 000.00 (0.00 %)
EPS:	$-0.830

FY	2022
Revenue:	$0
Gross Profit:	$-89 000.00 (0.00 %)
EPS:	$-0.970

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.650

Financial Reports:

No articles found.

NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.